IBC Advanced Alloys Corp. (TSXV:IB) Announces Convertible Security Funding Agreement

FRANKLIN, IN — February 17, 2026 — Leads & Copy — IBC Advanced Alloys Corp. (TSXV:IB)(OTCQB:IAALF) has entered into a convertible security funding agreement for a US$1,250,000 Convertible Security with Lind Global Fund III, LP, managed by The Lind Partners, LLC.

The Convertible Security will have a principal amount of US$1,250,000 and a pre-paid interest amount of US$250,000, giving it an aggregate face value of US$1,500,000. The term is 24 months.

The principal amount, less a US$62,500 closing fee, can be converted into common shares of IBC at the Investor’s option. The conversion price is set at C$0.205 per share, which was the last closing price of IBC’s common shares on the TSX Venture Exchange before the agreement.

Subject to certain conditions, including Exchange approval, the Investor has the right to invest up to an additional US$1,250,000 with an additional interest amount of up to US$250,000 with pro-rata terms and fees.

IBC is required to make monthly repayments of US$75,000 on the Face Value of the Convertible Security after the first four months until the Face Value is repaid. This repayment amount will be reduced by the amount converted into common shares. Subject to Exchange approval, IBC may also make a whole or partial Repayment in Common Shares, provided that certain conditions are met. Repayment Shares will be priced at 90% of the market closing price of the Common Shares on the day before issuance, but no lower than the Conversion Price. Under certain circumstances, IBC may be requested to make an additional cash payment.

The issuance of the Convertible Security will be completed under private placement rules with a 4 month plus one day hold period. Pre-paid interest will accrue monthly, and subject to Exchange approval, the Investor can convert accrued interest into common shares once every ninety days at 90% of the last closing price of IBC’s common shares on the day prior to conversion.

The Investor will receive 3,943,948 common share purchase warrants with an exercise price of C$0.2526, expiring 24 months from their date of issue. Additional warrants will be issued if the Investor proceeds with the Re-Investment Option, with an exercise price equal to 130% of the 20-day volume weighted average trading price of the Common Shares at the closing of the last trading day immediately prior to the date the Investor elects to proceed with the Re-Investment Option.

IBC can buy back the amount outstanding under the Convertible Security at any time. In the event of a change of control or if IBC exercises its buy-back right, the Investor may convert 100% of the pre-paid interest into common shares. The Investor may also convert up to 33% of the Principal Amount if IBC exercises its buy-back right.

If IBC increases its total debt above US$20 million, the Investor can require that the proceeds be used to repay any of the outstanding amount under the Convertible Security. Upon certain events of default, the Investor may declare all outstanding amounts immediately due and payable and/or terminate the Agreement.

The closing of the investment and issuance of the US$1,500,000 Convertible Security is expected around February 20, 2026, subject to regulatory approvals, including Exchange approval.

IBC intends to use the net proceeds from the funding for working capital and general corporate purposes.

IBC Advanced Alloys Corp. manufactures advanced copper alloys for industries including defense, aerospace, automotive, telecommunications, and precision manufacturing. Its common shares trade on the TSX-V under the symbol “IB” and the OTCQB under the symbol “IAALF”.

The Lind Partners is an institutional fund manager that provides growth capital to small- and mid-cap companies publicly traded in the US, Canada, Australia and the UK. Lind makes direct investments ranging from US$1 to US$30 million, invests in syndicated equity offerings and selectively buys on market.

Source: IBC Advanced Alloys Corp.

×

Welcome!

Biotech Reporter is the source most up-to-date real-time, direct-from-source News Tips and Story Leads.

By Subscribing you will receive Daily Biotech Update each day at 9:30 am ET (Market Open) in your inbox and you can unsubscribe any time.